PromotIng Optimal Treatment for Community-acquired PNeumonia in EmErgency Rooms

NANot yet recruitingINTERVENTIONAL
Enrollment

698

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

December 31, 2029

Study Completion Date

June 30, 2030

Conditions
Community-Acquired Pneumonia (CAP)Pneumonia
Interventions
DIAGNOSTIC_TEST

The novel care pathway intervention

The pathway uses already-ascertained data, bioMérieux Spotfire testing, and POC CRP testing to stratify patients into risk categories. The first step in the pathway will be POC CRP testing; children with CRP \> 60 mg/L will be deemed 'appreciable risk', whereas those with CRP \< 20 mg/L will be deemed 'low risk'. The CRP cut-offs of 20mg/L (more sensitive) and 60mg/L (more specific) were selected after reviewing the literature, with particular emphasis on meta-analyses; other large recent studies have also used 60mg/L as an upper cut-off for bacterial infection. Participants with CRP between 20-60mg/L will be categorized further to identify children either more likely to have bacterial pneumonia or more intolerant of misclassification. 'If they have O2 saturation \<95% AND tachypnoea as per age-specific norms, they will be 'appreciable risk' (\>60 bpm for age \<1 y, \>50 bpm for 1-2 y, \>40 bpm for 2-4 y, and \>30 bpm for \>4 y).

OTHER

Usual Care Alone

Participants will be recruited in the ED and will be managed as per the treating clinician; the study team will not influence management.

Trial Locations (6)

T3B 6A8

Alberta Children's hospital, Calgary

T6G 2B7

Stollery Children's Hospital, Edmonton

V6H 3N1

BC Children's Hospital, Vancouver

L8S 4K1

McMaster Children's Hospital, Hamilton

K1H 8M8

Children's Hospital of Eastern Ontario (CHEO), Ottawa

M5G 1E8

The Hospital for Sick Children, Toronto

All Listed Sponsors
lead

Jeffrey

OTHER

NCT07099976 - PromotIng Optimal Treatment for Community-acquired PNeumonia in EmErgency Rooms | Biotech Hunter | Biotech Hunter